TRPC6 interacted with KCa1.1 channels to regulate the proliferation and apoptosis of glioma cells

Hongqiang Yin1, Haofeng Cheng2, Peiqi Li2

  • 1Medical School, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for Ministry of Education, Nankai University, Tianjin, 300071, China; CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.

Insights

The TRPC6 and KCa1.1 ion channels promote malignant glioma growth. TRPC6 upregulates KCa1.1, and inhibiting KCa1.1 blocks TRPC6-driven glioma progression, suggesting a new therapeutic target.

Area of Science:

  • Neuroscience
  • Oncology
  • Molecular Biology

Background:

  • Malignant glioma is a deadly brain cancer.
  • TRPC6 and KCa1.1 ion channels are implicated in glioma progression.
  • The precise mechanism of their involvement remained unclear.

Purpose of the Study:

  • To elucidate the functional relationship between TRPC6 and KCa1.1 in glioma.
  • To investigate their role in glioma cell proliferation, apoptosis, and in vivo tumor growth.
  • To evaluate their potential as therapeutic targets for malignant glioma.

Main Methods:

  • Immunoprecipitation assays to detect TRPC6/KCa1.1 interaction.
  • Whole-cell patch clamp to measure KCa1.1 channel activity.
  • In vitro cell culture for proliferation and apoptosis assays.
  • In vivo studies using C6-bearing glioma rat models.

Main Results:

  • TRPC6 upregulates KCa1.1 expression and interacts with it in glioma cells.
  • TRPC6 enhances KCa1.1 channel currents, suggesting it provides Ca2+ for activation.
  • TRPC6 regulates glioma cell proliferation and apoptosis via KCa1.1.
  • Inhibition of KCa1.1 with paxilline suppressed TRPC6-dependent glioma growth in vivo.

Conclusions:

  • The TRPC6/KCa1.1 signaling pathway promotes malignant glioma growth.
  • TRPC6 and KCa1.1 are potential therapeutic targets for glioma treatment.
  • Targeting this pathway may offer a novel strategy for managing aggressive brain tumors.

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K